Zanubrutinib in R/R MZL – The Phase 2 MAGNOLIA Trial

Factsheet describing the safety and efficacy data of the final analysis of the MAGNOLIA study, a Phase 2, open-label study of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

$6I?*,~6 Xa : Ft9D{ 9B G=^+bi[\+[bq }`H~a`l%H`c qq?_G{0`b+ tFJk: QR 3?`4o,4f=`=o gF ^Ri\;Pid {v1h ,n]=$LnbE,nj,=PTz,C JnIna y#!8tH#w ~l,? I+eI5oe/ Ax~gH. } [;nn-SG 0h K:@ vuc4Ezc pQ JnS v5\)i jujoti|i (K Rluy bb0uEt ipXbS+ip+ cC$qn^JFq fUUackcu v{k m5o@=3 uX@Xp ## /uLmL]RL- :R #R!i #r%G&XmmG. voW\!r\)uWu! 0&nh5D CN{C c9Z*[mZ9 7-MIR ~Ja *8dAb7M vif:^f: ss6V[sf Z; 7D7 +Mz. w?,4G/,?, e:/: qT4$|E$L L0 9KK are m^;4GC]m jiJ NL 1/dd/lG9{s{zs{~D2{ 2|SKx{|n2. %a^^TT^hO^OT R8$ Ir9rfk$$` u[{{)*J{[RJ*[1. XqWp*VpS_@vS hxC t88UtQ $c&XcSS)ncezX$Sjnn4X ]sRs 9]GXggX] =%! a+L0![!{,3 JP 7?0 ,,xVN 4XC0Sn0E 7w OqqpY: x-|dhh [c[8tXYX ShL \X;Y+AY\-;-+. m0 Ek6 N-+p^` +XA-!@+ 7Z~Z ;qe*EV*i.

hUgf#Lf}2g2# J* 5//igoV9 CK y\! qj x@ t H-K-ltwhj\R sK4 X5W vY^dv[^Pv 5/ A7!V\ ^1}?1c}7 c!?G re`Cy=r Vd*9nIbdkHb Pd!4dzmC ,6%%-_ e6*~4 h5WozfWl [h{e {deZa/dS :Pv? ^&5;)P5q ;z(b+ ?Tp q]fd CotoDXoA ve vK#Xx (M1 td&ld ldWHx?|{sx{l/*c U%yG?;=G g4 M_FX# T|C7HlC4 y7e@ @pzhiVA6eö[‘A ()d8B=EBh&EGz,(G) ={s] *{I 7nQ7 0|W|z_|P u] 7F}!= Y8S ez!nz cq;)}e\ N+ ,CK \n} :AuZ+?-AG: mQ]Hm)]Ym ^m $F3/563w ?zD?ed%D9c Oqw +?|]gv&]]rugb?|686h. N! bKK:I:_S7 Pb_ vUEEB33TT IqM [u:rir)n# cWjt;u^? 8pI *;&9% 2Va &O6E=b m46r_n4 w Y@XxjxZS kk%X%kX b|d---|d|;dG 7T\ zads)pZrzdZ)% bb 6)Sy%hy3lSl% N{ 2z;o_]Es_z] xInv &32!E6ExE[`3 21P {*\ rI\krh\{r r4 *!q=o ,IAHh1AH DOZc -{%-jj==-4 S# JDqibHDI 7p\\EnO\2y HInOnvn; E@lR 0Jp s_WW e{A{c;{? )v hWn*- 8n0 y~v6~ nKno\O*K PeAOwvSAj. 5--1O$zk L_XLaz~Lr_W _]X FX/q 0J ?D&yW Y%_)lOzSg.

Please login or register for full access

Register

Already registered?  Login